Ocuphire Pharma Stock Fundamentals

OCUPDelisted Stock  USD 1.13  0.06  5.04%   
Ocuphire Pharma fundamentals help investors to digest information that contributes to Ocuphire Pharma's financial success or failures. It also enables traders to predict the movement of Ocuphire Stock. The fundamental analysis module provides a way to measure Ocuphire Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocuphire Pharma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Ocuphire Pharma Company Return On Equity Analysis

Ocuphire Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Ocuphire Pharma Return On Equity

    
  -0.36  
Most of Ocuphire Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ocuphire Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Ocuphire Pharma has a Return On Equity of -0.3601. This is 98.5% lower than that of the Biotechnology sector and 99.01% lower than that of the Health Care industry. The return on equity for all United States stocks is 16.16% higher than that of the company.

Ocuphire Pharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Ocuphire Pharma's current stock value. Our valuation model uses many indicators to compare Ocuphire Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ocuphire Pharma competition to find correlations between indicators driving Ocuphire Pharma's intrinsic value. More Info.
Ocuphire Pharma is considered to be number one stock in return on equity category among its peers. It is regarded third in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Ocuphire Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Ocuphire Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ocuphire Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ocuphire Pharma could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics of similar companies.
Ocuphire Pharma is currently under evaluation in return on equity category among its peers.

Ocuphire Fundamentals

About Ocuphire Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ocuphire Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocuphire Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocuphire Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan. Ocuphire Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.

Pair Trading with Ocuphire Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ocuphire Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ocuphire Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Ocuphire Stock

  0.72CAT Caterpillar Fiscal Year End 3rd of February 2025 PairCorr
  0.7WMT Walmart Aggressive PushPairCorr
  0.68AXP American Express Fiscal Year End 24th of January 2025 PairCorr
  0.66IBM International Business Fiscal Year End 22nd of January 2025 PairCorr
  0.64AA Alcoa Corp Fiscal Year End 15th of January 2025 PairCorr
The ability to find closely correlated positions to Ocuphire Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ocuphire Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ocuphire Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ocuphire Pharma to buy it.
The correlation of Ocuphire Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ocuphire Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ocuphire Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ocuphire Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Ocuphire Stock

If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA